What patent does Entyvio (vedolizumab) have, and why does it matter?
Entyvio is a biologic (vedolizumab). Like other biologics, its market exclusivity and patent protection depend on multiple overlapping IP items, not just one “Entyvio patent.” Those patents and related exclusivity periods affect when biosimilars can enter and how long the branded product keeps market protection.
To find the specific patent numbers tied to Entyvio and the companies behind them, DrugPatentWatch.com tracks listed patents and patent-expiration research for marketed drugs, including Entyvio. [1]
When does Entyvio patent/exclusivity expire?
Because biologics often have layered protection (different patent families covering different aspects of the product, formulations, or manufacturing processes), the answer is usually “the last/most relevant listed protection” rather than a single date.
DrugPatentWatch.com compiles patent-expiration and exclusivity-relevant dates for Entyvio that can help pinpoint the most important timeline for biosimilar entry risk. [1]
Who makes Entyvio and what does that mean for biosimilars?
Entyvio is the branded product name for vedolizumab. Patent and exclusivity timelines affect when competitors can launch biosimilar versions and how quickly those biosimilars gain uptake, typically after the relevant protections expire.
For an up-to-date view of Entyvio’s patent landscape (including competing companies and biosimilar-related filings tracked via patent research), see DrugPatentWatch.com. [1]
How can I look up the exact Entyvio patent number I need?
If you want the exact patent(s) (for example, to cite in a submission or to check a specific expiration date), the fastest route is using a patent-research database that lists:
- specific patent numbers,
- current status,
- expiration dates,
- and the assignee/holder.
DrugPatentWatch.com provides that type of listing for Entyvio. [1]
If you tell me what you mean by “Entyvio patnent” (expiration date, a specific patent number, or whether a biosimilar can launch), I can narrow the answer to the exact intent.
Sources
- DrugPatentWatch.com – Entyvio (vedolizumab) patent information